EUVIMEDEUVIMED entdecken
Crossref

Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium‐glucose cotransporter‐2 inhibitor and glucagon‐like peptide ‐1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease

RECAP study group, Shunichiro Tsukamoto, Kazuo Kobayashi iD, Masao Toyoda, Atsuhito Tone, Daiji Kawanami, Daisuke Suzuki, Daisuke Tsuriya, Hideo Machimura, Hidetoshi Shimura, Hiromichi Wakui iD, Hiroshi Takeda und 20 weitere

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15652 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von RECAP study group und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Drug Therapy, Combination. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To conduct a post hoc subgroup analysis of patients with type 2 diabetes (T2D) from the RECAP study, who were treated with sodium‐glucose cotransporter‐2 (SGLT2) inhibitor and glucagon‐like peptide 1 receptor agonist (GLP‐1RA) combination therapy, focusing only on those patients who had chronic kidney disease (CKD), to examine whether the composite renal outcome differed between those who received SGLT2 inhibitor treatment first and those who received a GLP‐1RA first.

Methods

We included 438 patients with CKD (GLP‐1RA‐first group, n = 223; SGLT2 inhibitor‐first group, n = 215) from the 643 T2D patients in the RECAP study. The incidence of the composite renal outcome, defined as progression to macroalbuminuria and/or a ≥50% decrease in estimated glomerular filtration rate (eGFR), was analysed using a propensity score (PS)‐matched model. Furthermore, we calculated the win ratio for these composite renal outcomes, which were weighted in the following order: (1) both a ≥50% decrease in eGFR and progression to macroalbuminuria; (2) a decrease in eGFR of ≥50% only; and (3) progression to macroalbuminuria only.

Results

Using the PS‐matched model, 132 patients from each group were paired. The incidence of renal composite outcomes did not differ between the two groups (GLP‐1RA‐first group, 10%; SGLT2 inhibitor‐first group, 17%; odds ratio 1.80; 95% confidence interval [CI] 0.85 to 4.26; p = 0.12). The win ratio of the GLP‐1RA‐first group versus the SGLT2 inhibitor‐first group was 1.83 (95% CI 1.71 to 1.95; p < 0.001).

Conclusion

Although the renal composite outcome did not differ between the two groups, the win ratio of the GLP‐1RA‐first group versus the SGLT2 inhibitor‐first group was significant. These results suggest that, in GLP‐1RA and SGLT2 inhibitor combination therapy, the addition of an SGLT2 inhibitor to baseline GLP‐1RA treatment may lead to more favourable renal outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Renal Insufficiency, ChronicDrug Therapy, CombinationDiabetic NephropathiesGlomerular Filtration RateGlucagon-Like Peptide-1 Receptor AgonistsHumansMaleFemaleMiddle AgedAgedDisease ProgressionAlbuminuriaHypoglycemic AgentsTreatment OutcomeCardiovascular Diseases

Stichwörter der Autor:innen

combination treatmentglucagon‐like peptide 1 receptor agonistpreceding drugrenal outcomesodium‐glucose cotransporter 2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
  • Department of Internal Medicine, Diabetes Center, Okayama Saiseikai General Hospital, Okayama, Japan.
  • Department of Endocrinology and Diabetes, Fukuoka University School of Medicine, Fukuoka, Japan.
  • Suzuki Diabetes Clinic, Atsugi, Japan.
  • Division of Endocrinology and Metabolism, 2nd Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

ORCID-Profile: Kazuo Kobayashi, Hiromichi Wakui, Hisashi Yokomizo, Moritsugu Kimura, Yuichi Takashi

Zitieren

APA

RECAP study group, Tsukamoto, S., Kobayashi, K., Toyoda, M., Tone, A., Kawanami, D., Suzuki, D., Tsuriya, D., Machimura, H., Shimura, H., Wakui, H., Takeda, H., Yokomizo, H., Takeshita, K., Chin, K., Kanasaki, K., Miyauchi, M., Saburi, M., Morita, M., …, & Tamura, K. (2024). Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium‐glucose cotransporter‐2 inhibitor and glucagon‐like peptide ‐1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15652

Vancouver

RECAP study group, Tsukamoto S, Kobayashi K, Toyoda M, Tone A, Kawanami D, et al. Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium‐glucose cotransporter‐2 inhibitor and glucagon‐like peptide ‐1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15652

BibTeX
@article{RECAPstudygroup2024,
  author = {RECAP study group, RECAP study group and Tsukamoto, Shunichiro and Kobayashi, Kazuo and Toyoda, Masao and Tone, Atsuhito and Kawanami, Daiji and Suzuki, Daisuke and Tsuriya, Daisuke and Machimura, Hideo and Shimura, Hidetoshi and Wakui, Hiromichi and Takeda, Hiroshi and Yokomizo, Hisashi and Takeshita, Kei and Chin, Keiichi and Kanasaki, Keizo and Miyauchi, Masaaki and Saburi, Masuo and Morita, Miwa and Yomota, Miwako and Kimura, Moritsugu and Hatori, Nobuo and Nakajima, Shinichi and Ito, Shun and Murata, Takashi and Matsushita, Takaya and Furuki, Takayuki and Hashimoto, Takuya and Umezono, Tomoya and Muta, Yoshimi and Takashi, Yuichi and Tamura, Kouichi},
  title = {Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium‐glucose cotransporter‐2 inhibitor and glucagon‐like peptide ‐1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15652}
}
Kostenlos starten →